[시장보고서]항당뇨병제 시장 규모, 점유율, 동향 분석 보고서 : 약제 클래스별, 당뇨 유형별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

항당뇨병제 시장 규모, 점유율, 동향 분석 보고서 : 약제 클래스별, 당뇨 유형별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

Antidiabetics Market Size, Share & Trends Analysis Report By Drug Class, By Diabetes Type, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

상품코드 : 1726201

리서치사 : Grand View Research

발행일 : 2025년 04월

페이지 정보 : 영문 100 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,575,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,017,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,899,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

항당뇨병제 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 항당뇨병제 시장 규모는 2030년까지 1,685억 5,000만 달러에 이르며, 2025-2030년의 CAGR은 10.75%를 나타낼 것으로 예측됩니다.

당뇨병의 유병률 증가가 이 시장의 주요 촉진요인입니다. 불규칙한 식생활이나 비만 증가 또한 대상 질환의 이환율을 유발하는 것으로 제품 수요를 밀어 올릴 것으로 예측됩니다.

인슐린은 가장 수익성이 높은 부문이며, 시장 규모는 200억 달러를 넘었습니다. 인슐린은 이 시장에서 가장 유리한 부문 중 하나이기도 합니다.

항당뇨병제 시장 보고서 하이라이트

새롭게 승인된 자누비아, 네시나, 온그리자 등의 DPP-4 억제제는 1일 1회의 투여 요법과 안전성 프로파일이 평가되어 급속히 시장에 침투했습니다.
북미는 2024년 시장의 41.48%를 차지했습니다. 가장 성숙한 항당뇨병제 시장이었던 인슐린 제제 및 기타 항당뇨병제의 높은 시장 침투율과 세련된 상환제도의 존재가 이 지역 시장 성장을 견인할 것으로 예측됩니다.
아시아태평양은 제조업체에 유리한 장래의 성장 기회를 가져다 줄 것으로 기대되고 있습니다.
항당뇨병제 시장의 주요 진출기업은 AstraZeneca plc, Bayer AG, 다케다 약품 공업, Eli Lilly and Company, Boehringer Ingelheim, Bristol-Myers Squibb Company, Merck & Co.Inc., Johnson & Johnson Services Inc., Pfizer가 있습니다.
시장은 과점적인 성질을 가지고 있으며, 소수의 기업이 시장의 70% 이상을 차지하고 있습니다.

시장 계통의 전망
시장 동향과 전망
시장 역학
- 당뇨병 이환율의 상승
- 조사와 기술의 진보
- 의식의 향상과 조기 개입
시장 성장 억제요인 분석
- 높은 개발 비용
- 부작용과 안전성에 대한 우려
산업 분석도구
- Porter's Five Forces 분석
- PESTEL 분석
가격 분석
파이프라인 분석

제4장 항당뇨병제 시장 : 약제 클래스의 비즈니스 분석

약제 클래스 시장 점유율(2024년, 2030년)
약제 클래스 부문 대시보드
시장 규모와 예측과 동향 분석 보고서 - 약제 클래스별(2018-2030년)
인슐린
GLP-1 수용체 작용제
DPP-4 억제제
SGLT2 억제제
DPP-4 억제제
기타

제5장 항당뇨병제 시장 : 당뇨 유형의 비즈니스 분석

당뇨 유형 시장 점유율(2024년, 2030년)
당뇨 유형 부문 대시보드
시장 규모, 예측, 동향 분석 - 당뇨 유형별(2018-2030년)
유형 1
유형 2

제6장 항당뇨병제 시장 : 투여 경로의 비즈니스 분석

투여 경로 시장 점유율(2024년, 2030년)
투여 경로 부문 대시보드
시장 규모, 예측, 동향 분석 - 투여 경로별(2018-2030년)
경구
피하
정맥 내

제7장 항당뇨병제 시장 : 유통 채널의 비즈니스 분석

유통 채널 시장 점유율(2024년, 2030년)
유통 채널 부문 대시보드
시장 규모, 예측, 동향 분석 - 유통 채널별(2018-2030년)
온라인 약국
병원 약국
소매 약국

제8장 항당뇨병제 시장 : 지역별, 추정 및 동향 분석

지역별 시장 점유율 분석(2024년, 2030년)
지역별 시장 대시보드
시장 규모, 예측, 동향 분석(2018-2030년)
북미
- 국가별(2018-2030년)
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제9장 경쟁 구도

참가자 개요
기업의 시장 포지셔닝 분석
기업 분류
전략 매핑
기업 프로파일/상장 기업
- Novo Nordisk
- Eli Lilly and Company
- Sanofi
- Merck & Co., Inc.
- AstraZeneca plc
- Johnson & Johnson Services Inc.
- Boehringer Ingelheim
- Novartis AG
- Takeda Pharmaceutical Company
- Bayer AG

KTH

영문 목차

영문목차

Antidiabetics Market Growth & Trends:

The global antidiabetics market size is expected to reach USD 168.55 billion by 2030, expanding at a CAGR of 10.75% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of diabetes is the primary driver of this market. Growth in irregular dietary habits and obesity is also expected to boost product demand by triggering incidence rates of target diseases. Future commercialization of products currently in the pipeline and the presence of large untapped opportunities in the emerging Asia Pacific and Latin American markets is expected to fuel future market growth.

Insulin was the most revenue-generating segment and its market was valued at over USD 20.0 billion in 2013. Insulin is also one of the most lucrative segments of this market. The introduction of new products exhibiting higher efficacy coupled with the presence of favorable government initiatives are some factors attributing to its market attractiveness.

Antidiabetics Market Report Highlights:

The rapid uptake of newly approved DPP-4 inhibitors such as Januvia, Nesina, and Onglyza on account of their once-daily dosage regimens and safety profiles catalyzed the growth of this market.
North America was the most mature antidiabetics market in 2024 accounting for over 41.48% of the market High market penetration of insulin and other antidiabetics and the presence of sophisticated reimbursement framework are expected to drive regional market growth.
Asia Pacific is expected to present manufacturers with lucrative future growth opportunities. Large presence of unmet patient needs and rapidly improving healthcare infrastructure are some factors expected to drive market growth in the region. The market is also expected to be driven by the introduction of cheaper products made available by local manufacturers.
Some key market players of antidiabetics include AstraZeneca plc, Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim, Bristol-Myers Squibb Company, Merck & Co. Inc, Johnson & Johnson Services Inc. and Pfizer.
The market is oligopolistic in nature with few players accounting for over 70% of the market. Extensive R&D investments aimed at new product development and entering new markets via government contracts are the key sustainability strategies adopted by these organizations.

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Segment Definitions
- 1.2.1. Drug Class
- 1.2.2. Diabetes Type
- 1.2.3. Distribution Channel
- 1.2.4. Route of Administration
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information or Data Analysis:
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Validation
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
- 3.3.1. Rising Diabetes Prevalence
- 3.3.2. Advancements in Research and Technology
- 3.3.3. Increasing Awareness and Early Intervention
3.4. Market Restraint Analysis
- 3.4.1. High Development Costs
- 3.4.2. Side Effects and Safety Concerns
3.5. Industry Analysis Tools
- 3.5.1. Porter's Five Forces Analysis
- 3.5.2. PESTEL Analysis
3.6. Pricing Analysis
3.7. Pipeline Analysis

Chapter 4. Antidiabetics Market: Drug Class Business Analysis

4.1. Drug Class Market Share, 2024 & 2030
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. Insulin
- 4.4.1. Insulin Market, 2018 - 2030 (USD Million)
  - 4.4.1.1. Insulin Market, By Type
    - 4.4.1.1.1. Long-acting insulin
      - 4.4.1.1.1.1. Long-acting insulin market, 2018 - 2030 (USD Million)
    - 4.4.1.1.2. Premix insulin
      - 4.4.1.1.2.1. Premix insulin market, 2018 - 2030 (USD Million)
    - 4.4.1.1.3. Fast-acting insulin
      - 4.4.1.1.3.1. Fast-acting insulin market, 2018 - 2030 (USD Million)
    - 4.4.1.1.4. Human insulin
      - 4.4.1.1.4.1. Human insulin market, 2018 - 2030 (USD Million)
4.5. GLP-1 Receptor Agonists
- 4.5.1. GLP-1 Receptor Agonists Market, 2018 - 2030 (USD Million)
4.6. DPP- 4 Inhibitors
- 4.6.1. DPP- 4 Inhibitors Market, 2018 - 2030 (USD Million)
4.7. SGLT2 Inhibitors
- 4.7.1. SGLT2 Inhibitors Market, 2018 - 2030 (USD Million)
4.8. DPP-4 Inhibitors
- 4.8.1. DPP- 4 Inhibitors Market, 2018 - 2030 (USD Million)
4.9. Others
- 4.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Antidiabetics Market: Diabetes Type Business Analysis

5.1. Diabetes Type Market Share, 2024 & 2030
5.2. Diabetes Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Diabetes Type , 2018 to 2030 (USD Million)
5.4. Type 1
- 5.4.1. Type 1 Market, 2018 - 2030 (USD Million)
5.5. Type 2
- 5.5.1. Type 2 Market, 2018 - 2030 (USD Million)

Chapter 6. Antidiabetics Market: Route of Administration Business Analysis

6.1. Route of Administration Market Share, 2024 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Oral
- 6.4.1. Oral Market, 2018 - 2030 (USD Million)
6.5. Subcutaneous
- 6.5.1. Subcutaneous Market, 2018 - 2030 (USD Million)
6.6. Intravenous
- 6.6.1. Intravenous Market, 2018 - 2030 (USD Million)

Chapter 7. Antidiabetics Market: Distribution Channel Business Analysis

7.1. Distribution Channel Market Share, 2024 & 2030
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
7.4. Online Pharmacies
- 7.4.1. Online Pharmacies Market, 2018 - 2030 (USD Million)
7.5. Hospital Pharmacies
- 7.5.1. Hospital Pharmacies, Market, 2018 - 2030 (USD Million)
7.6. Retail Pharmacies
- 7.6.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Antidiabetics Market: Regional Estimates & Trend Analysis

8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
- 8.4.1. North America Antidiabetics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 8.4.2. U.S.
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. Target Disease Prevalence
  - 8.4.2.3. Regulatory Framework
  - 8.4.2.4. Reimbursement Framework
  - 8.4.2.5. U.S. Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. Canada
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Target Disease Prevalence
  - 8.4.3.3. Regulatory Framework
  - 8.4.3.4. Reimbursement Framework
  - 8.4.3.5. U.S. Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. Mexico
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Target Disease Prevalence
  - 8.4.4.3. Regulatory Framework
  - 8.4.4.4. Reimbursement Framework
  - 8.4.4.5. Mexico Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Europe
- 8.5.1. Europe Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. UK
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. Target Disease Prevalence
  - 8.5.2.3. Regulatory Framework
  - 8.5.2.4. Reimbursement Framework
  - 8.5.2.5. Uk Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Germany
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Target Disease Prevalence
  - 8.5.3.3. Regulatory Framework
  - 8.5.3.4. Reimbursement Framework
  - 8.5.3.5. Germany Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.4. France
  - 8.5.4.1. Key Country Dynamics
  - 8.5.4.2. Target Disease Prevalence
  - 8.5.4.3. Regulatory Framework
  - 8.5.4.4. Reimbursement Framework
  - 8.5.4.5. France Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.5. Italy
  - 8.5.5.1. Key Country Dynamics
  - 8.5.5.2. Target Disease Prevalence
  - 8.5.5.3. Regulatory Framework
  - 8.5.5.4. Reimbursement Framework
  - 8.5.5.5. Italy Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.6. Spain
  - 8.5.6.1. Key Country Dynamics
  - 8.5.6.2. Target Disease Prevalence
  - 8.5.6.3. Regulatory Framework
  - 8.5.6.4. Reimbursement Framework
  - 8.5.6.5. Spain Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.7. Denmark
  - 8.5.7.1. Key Country Dynamics
  - 8.5.7.2. Target Disease Prevalence
  - 8.5.7.3. Regulatory Framework
  - 8.5.7.4. Reimbursement Framework
  - 8.5.7.5. Denmark Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.8. Sweden
  - 8.5.8.1. Key Country Dynamics
  - 8.5.8.2. Target Disease Prevalence
  - 8.5.8.3. Regulatory Framework
  - 8.5.8.4. Reimbursement Framework
  - 8.5.8.5. Sweden Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.9. Norway
  - 8.5.9.1. Key Country Dynamics
  - 8.5.9.2. Target Disease Prevalence
  - 8.5.9.3. Regulatory Framework
  - 8.5.9.4. Reimbursement Framework
  - 8.5.9.5. Norway Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Asia Pacific
- 8.6.1. Asia Pacific Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.2. Japan
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. Target Disease Prevalence
  - 8.6.2.3. Regulatory Framework
  - 8.6.2.4. Reimbursement Framework
  - 8.6.2.5. Japan Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. China
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. Target Disease Prevalence
  - 8.6.3.3. Regulatory Framework
  - 8.6.3.4. Reimbursement Framework
  - 8.6.3.5. China Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. India
  - 8.6.4.1. Key Country Dynamics
  - 8.6.4.2. Target Disease Prevalence
  - 8.6.4.3. Regulatory Framework
  - 8.6.4.4. Reimbursement Framework
  - 8.6.4.5. India Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. Australia
  - 8.6.5.1. Key Country Dynamics
  - 8.6.5.2. Target Disease Prevalence
  - 8.6.5.3. Regulatory Framework
  - 8.6.5.4. Reimbursement Framework
  - 8.6.5.5. Australia Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.6. South Korea
  - 8.6.6.1. Key Country Dynamics
  - 8.6.6.2. Target Disease Prevalence
  - 8.6.6.3. Regulatory Framework
  - 8.6.6.4. Reimbursement Framework
  - 8.6.6.5. South Korea Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.7. Thailand
  - 8.6.7.1. Key Country Dynamics
  - 8.6.7.2. Target Disease Prevalence
  - 8.6.7.3. Regulatory Framework
  - 8.6.7.4. Reimbursement Framework
  - 8.6.7.5. Thailand Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.7. Latin America
- 8.7.1. Latin America Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.2. Brazil
  - 8.7.2.1. Key Country Dynamics
  - 8.7.2.2. Target Disease Prevalence
  - 8.7.2.3. Regulatory Framework
  - 8.7.2.4. Reimbursement Framework
  - 8.7.2.5. Japan Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7.3. Argentina
  - 8.7.3.1. Key Country Dynamics
  - 8.7.3.2. Target Disease Prevalence
  - 8.7.3.3. Regulatory Framework
  - 8.7.3.4. Reimbursement Framework
  - 8.7.3.5. China Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8. Middle East and Africa
- 8.8.1. Middle East and Africa Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.2. South Africa
  - 8.8.2.1. Key Country Dynamics
  - 8.8.2.2. Target Disease Prevalence
  - 8.8.2.3. Regulatory Framework
  - 8.8.2.4. Reimbursement Framework
  - 8.8.2.5. South Africa Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.3. Saudi Arabia
  - 8.8.3.1. Key Country Dynamics
  - 8.8.3.2. Target Disease Prevalence
  - 8.8.3.3. Regulatory Framework
  - 8.8.3.4. Reimbursement Framework
  - 8.8.3.5. Saudi Arabia Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.4. UAE
  - 8.8.4.1. Key Country Dynamics
  - 8.8.4.2. Target Disease Prevalence
  - 8.8.4.3. Regulatory Framework
  - 8.8.4.4. Reimbursement Framework
  - 8.8.4.5. UAE Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8.5. Kuwait
  - 8.8.5.1. Key Country Dynamics
  - 8.8.5.2. Target Disease Prevalence
  - 8.8.5.3. Regulatory Framework
  - 8.8.5.4. Reimbursement Framework
  - 8.8.5.5. Kuwait Antidiabetics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
- 9.5.1. Novo Nordisk
  - 9.5.1.1. Overview
  - 9.5.1.2. Financial Performance
  - 9.5.1.3. Product Benchmarking
  - 9.5.1.4. Strategic Initiatives
- 9.5.2. Eli Lilly and Company
  - 9.5.2.1. Overview
  - 9.5.2.2. Financial Performance
  - 9.5.2.3. Product Benchmarking
  - 9.5.2.4. Strategic Initiatives
- 9.5.3. Sanofi
  - 9.5.3.1. Overview
  - 9.5.3.2. Financial Performance
  - 9.5.3.3. Product Benchmarking
  - 9.5.3.4. Strategic Initiatives
- 9.5.4. Merck & Co., Inc.
  - 9.5.4.1. Overview
  - 9.5.4.2. Financial Performance
  - 9.5.4.3. Product Benchmarking
  - 9.5.4.4. Strategic Initiatives
- 9.5.5. AstraZeneca plc
  - 9.5.5.1. Overview
  - 9.5.5.2. Financial Performance
  - 9.5.5.3. Product Benchmarking
  - 9.5.5.4. Strategic Initiatives
- 9.5.6. Johnson & Johnson Services Inc.
  - 9.5.6.1. Overview
  - 9.5.6.2. Financial Performance
  - 9.5.6.3. Product Benchmarking
  - 9.5.6.4. Strategic Initiatives
- 9.5.7. Boehringer Ingelheim
  - 9.5.7.1. Overview
  - 9.5.7.2. Financial Performance
  - 9.5.7.3. Product Benchmarking
  - 9.5.7.4. Strategic Initiatives
- 9.5.8. Novartis AG
  - 9.5.8.1. Overview
  - 9.5.8.2. Financial Performance
  - 9.5.8.3. Product Benchmarking
  - 9.5.8.4. Strategic Initiatives
- 9.5.9. Takeda Pharmaceutical Company
  - 9.5.9.1. Overview
  - 9.5.9.2. Financial Performance
  - 9.5.9.3. Product Benchmarking
  - 9.5.9.4. Strategic Initiatives
- 9.5.10. Bayer AG
  - 9.5.10.1. Overview
  - 9.5.10.2. Financial Performance
  - 9.5.10.3. Product Benchmarking
  - 9.5.10.4. Strategic Initiatives